Introduction:
Simtra BioPharma Solutions invests US$250 million to construct new sterile fill/finish manufacturing site in Indiana, USA.
Features:
A new, state of the art 150,000 square foot building is designed to accommodate two high-speed automated isolator syringe fill lines and a new high-speed isolator vial line boasting three 30 square metre lyophilisers. Each process suite within the new structure will feature dedicated formulation and compounding rooms.
Additionally, the expansion project will introduce a specialised clinical line tailored to bolster development and clinical operations. This line will make efficient use of the existing facility infrastructure.
This will enable the Bloomington campus to more effectively handle projects in the early stages of development (Phase I or II) and keep projects onsite to scale up towards commercialisation.
Construction of the new facility is slated to commence in June 2024 and is expected to span a two-year period, with GMP compliance targeted for late 2026.
The new campus is projected to generate hundreds of job opportunities in Bloomington.
Specifications:
Name Simtra BioPharma Solutions
Type New Construction
Budget US$250 million
Year 2026
